Novartis AG Pharma Division Head Supports Ministry Panel’s Diovan Investigation Interim Report, Refuses to Comment on Whether Ads Were Exaggerated

David Epstein, a pharmaceutical division head of Novartis AG, said the company agrees with a health ministry panel’s interim report on the Diovan (valsartan) clinical study scandal, which claims that both universities and Novartis Pharma K.K. involved in the scandal...read more